Bigfoot Medical, which is developing smart pens for diabetes management, closed an Abbott-led series C round after securing $45m in the first tranche in January.
US-based diabetes management technology developer Bigfoot Biomedical completed a $55m series C round yesterday that was led by medical device manufacturer Abbott.
The round included Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management, all of which took part in the $45m first tranche five months ago. New investors joined the round for the final close, though only charity Smile Group was identified.
Bigfoot is working on a smart pen that will be capable of determining the…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
